Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
Public ClinicalTrials.gov record NCT01032915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
Study identification
- NCT ID
- NCT01032915
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- May 31, 2011
- Completion
- May 31, 2011
- Last update posted
- Nov 4, 2015
2010 – 2011
United States locations
- U.S. sites
- 24
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sall Research Medical Center | Artesia | California | 90701 | — |
| Novartis Investigative Site | Artesia | California | 90704 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Retina-Vitreous Assoc. Medical Group | Beverly Hills | California | 90211 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30322 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40202 | — |
| University of Louisville Opthamology | Louisville | Kentucky | 40202 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21205-2005 | — |
| The Wilmer Eye Institute | Baltimore | Maryland | 21287 | — |
| Massachusets Eye Research and Surgery Institution (MERSI) | Cambridge | Massachusetts | 02142 | — |
| Novartis Investigative Site | Cambridge | Massachusetts | 02142 | — |
| Novartis Investigative Site | Teaneck | New Jersey | 07666 | — |
| The Cornea and Laser Institute and UMDNJ | Teaneck | New Jersey | 07666 | — |
| Charlotte Eye, Ear, Nose, and Throat Associates | Belmont | North Carolina | 28012 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| OHSU, Casey Eye Institute | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Arlington | Texas | 76012 | — |
| Texas Retina Associates | Arlington | Texas | 76012 | — |
| Houston Eye Associates | Houston | Texas | 77025 | — |
| Novartis Investigative Site | Houston | Texas | 77025 | — |
| University of Washington | Seattle | Washington | 98104 | — |
| Novartis Investigative Site | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01032915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2015 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01032915 live on ClinicalTrials.gov.